Table 2.

Multivariate analysis for progression-free and overall survival

Endpoint	Subgroup	N		HR	95% CI	P value
PFS	PD-L1 status (TPS ≥1)	n 110		0.54	(0.33 to 0.87)	0.012
	Stromal CD8+ (>697)			0.59	(0.34 to 1.01)	0.055
	Sex (male)			0.87	(0.54 to 1.39)	0.560
	Age (>62)			1.04	(0.65 to 1.65)	0.868
	Intratumoral CD163+ (>472 cells/mm2)			1.80	(1.10 to 2.93)	0.019
	Previous treatment line (>1)			1.82	(1.05 to 3.15)	0.034
	Performance status (>1)			1.96	(1.07 to 3.59)	0.030
OS	PD-L1 status (TPS ≥1)	110		0.50	(0.27 to 0.92)	0.027
	Stromal CD8+ (>697)			0.68	(0.36 to 1.28)	0.233
	Sex (male)			0.72	(0.41 to 1.29)	0.276
	Age (>62)			1.33	(0.77 to 2.31)	0.308
	Previous treatment line (>1)			2.05	(1.10 to 3.80)	0.023
	Intratumoral CD163+ (>472 cells/mm2)			2.69	(1.45 to 4.99)	0.002
	Performance status (>1)			3.82	(1.92 to 7.60)	<0.001

OS, overall survival; PD-L1, programmed cell death ligand 1; PFS, progression -free survival; TPS, tumor proportion score.